Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
55.94 USD +0.13% Intraday chart for LivaNova PLC -0.60% +8.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Down Wednesday Afternoon MT
LivaNova Says Sleep Apnea Study Likely to Meet Primary Efficacy Endpoint; Shares Jump MT
LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea CI
Transcript : LivaNova PLC Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:45 AM
LivaNova Proposes $300 Million Private Placement of Notes MT
Barclays Adjusts Price Target on LivaNova to $61 From $57, Keeps Equalweight Rating MT
Barclays Raises Price Target on LivaNova to $61 From $57, Maintains Equalweight Rating MT
Wolfe Research Adjusts LivaNova's Price Target to $65 From $58, Keeps Outperform Rating MT
Baird Adjusts LivaNova's Price Target to $62 From $56, Keeps Neutral Rating MT
Mizuho Securities Adjusts Price Target on LivaNova to $75 From $70, Maintains Buy Rating MT
Needham Adjusts Price Target on LivaNova to $72 From $62, Keeps Buy Rating MT
Transcript : LivaNova PLC, Q4 2023 Earnings Call, Feb 21, 2024
LivaNova's Q4 Adjusted Earnings, Revenue Increase; Sets 2024 Guidance MT
Earnings Flash (LIVN) LIVANOVA Reports Q4 Revenue $310.1M, vs. Street Est of $287.7M MT
Earnings Flash (LIVN) LIVANOVA Reports Q4 EPS $0.87, vs. Street Est of $0.77 MT
LivaNova PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Livanova plc Provides Earnings Guidance for the Full-Year 2024 CI
LivaNova PLC Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023 CI
Mizuho Securities Upgrades LivaNova to Buy From Neutral, Raises Price Target to $70 From $60 MT
LivaNova Names Vladimir Makatsaria as Chief Executive MT
FTSE 100 Closes Down 0.03% After US Data Hit Rate-Cut Hopes DJ
LivaNova PLC Announces Board Changes, Effective on March 1, 2024 CI
LivaNova PLC Announces CEO Changes, Effective on March 1, 2024 CI
Chart LivaNova PLC
More charts
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
55.94 USD
Average target price
66.5 USD
Spread / Average Target
+18.88%
Consensus
  1. Stock
  2. Equities
  3. Stock LivaNova PLC - Nasdaq
  4. News LivaNova PLC
  5. Update: LivaNova Shares Fall Following Launch of $300 Million Share Offering